3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
4
Carcinoma, Renal Cell
4
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Castration-resistant Prostate Cancer
2
Urologic Neoplasms
1
Stomach Neoplasms
1
Osteosarcoma
1
Lymphatic Metastasis
1
Ependymoma
1
Colonic Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Breast Neoplasms
1
Bone Neoplasms
1
Adenocarcinoma
1
Interventions
Oxaliplatin
46
Gemcitabine
45
Fluorouracil
40
Capecitabine
31
pembrolizumab
29
Leucovorin
29
Docetaxel
27
Cisplatin
25
Paclitaxel
23
Irinotecan
18
Carboplatin
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
17
Pemetrexed
15
Albumin-Bound Paclitaxel
15
Radiotherapy
14
Nivolumab
12
Ramucirumab
11
Cyclophosphamide
11
Trastuzumab
8
Erlotinib Hydrochloride
8
Taxes
7
Radiosurgery
7
Drug Therapy
7
cemiplimab
6
zolbetuximab
5
trastuzumab deruxtecan
5
regorafenib
5
durvalumab
5
Sorafenib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma
×
Metastasectomy
×
Clear all
NCT06121700
2023-11-08
Miracle-G
Fudan University
Phase 2
Recruiting
55 enrolled